Sernova Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing regenerative medicine therapeutics, including its proprietary Cell Pouch technology. Concerns arise from its extremely low current ratio of 0.02, indicating significant liquidity issues, and a negative return on assets of -447.3%, reflecting operational challenges. However, the recent price increase of 4.55% may suggest some investor optimism. Overall, while Sernova has innovative potential, its financial health raises red flags that warrant caution.
Loading financial metrics...
Company has $84K in cash but burned $3.7M last quarter. At this burn rate, only 0.0 quarters of runway remain without additional financing.
Company posted a loss of $-18.5M over the last year, representing Infinity% of revenue.
Debt of $4.7M is 56.1x the company's cash position of $84K.
Operating cash flow has been negative for 3 consecutive quarters, burning $14.7M over the last year.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Biotechnology companies of a similar size
Based on 2025-Q3 (July 31, 2025)